Monetary Policy and Funding Costs for Biopharma: The FOMC's inflation stance and potential for higher interest rates directly impact the cost of capital for clinical-stage biopharmaceutical companies like Alzamend Neuro, which rely heavily on financing for their extensive R&D and clinical trials. This could make it more challenging and expensive to secure necessary funding.

Inflationary Pressures on Operational Costs: Anticipated US March CPI data revealing inflation trends means that rising costs for supplies, research materials, and personnel could increase Alzamend Neuro's operational expenses, potentially impacting their burn rate and the timeline for drug development.

Sector-Specific Investor Sentiment and Clinical Trial Success: Investor confidence in the biotechnology sector, particularly for companies focused on neurodegenerative diseases with ongoing clinical trials, is a significant driver. The high-risk, high-reward nature of drug development means that news of clinical trial progress (or setbacks) and general market appetite for speculative biopharma investments will heavily influence ALZN's stock performance.